What We're Reading: Page 46
Industry reads hand-picked by our editors
Jul 23, 2024
-
Reuters
Drug giants eye China for deals despite growing Sino-US tensions
-
Financial Times
Novartis warns prostate cancer drug price will remain high
-
FirstWord Pharma
With IPO on ice, radiopharm developer Telix to raise nearly $400M in bond sale
-
KFF Health News
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Jul 22, 2024
-
Axios
Biden’s fragile legacy on health care
-
C&EN
Lead seeks to lead in radiopharma
-
MIT Technology Review
Why we need safeguards against genetic discrimination
Jul 19, 2024
Jul 18, 2024
Jul 17, 2024
-
Fierce Pharma
Inside the FDA concerns that sank Hengrui’s PD-1 drug filing
-
Financial Times
The questions behind the Ozempic baby boom
-
The Wall Street Journal
Think You Will Live to 100? These Scientists Think You’re Wrong
Jul 16, 2024
Jul 15, 2024
-
The New York Times
Promised Cures, Tainted Cells: How Cord Blood Banks Mislead Parents
-
Reuters
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market
-
Axios
Medicare proposes payment for digital mental health therapies
-
FirstWord Pharma
Legend jumps on takeout chatter amid Carvykti success
Previous
